Background

Sandra is a long-term member of the Immune Therapies group and has worked with Professor Hogarth since 1996. She is part of the Cancer, Inflammation and Infectious Diseases projects which focus on antibody and Fc receptor therapeutic research and development. She also worked with Professor Geoff Pietersz from 1998 to 2014 focusing on antibody-drug conjugate therapeutic research and development.

Positions

• 2006-present: Senior Research Assistant, Burnet Institute, Australia
• 1996-2005: Research Assistant, Austin Research Institute, Australia

Qualifications

• 1995: BSc, Monash University, Australia

Projects (4)

Current (4)

• 

  Fc Receptor Targeted Treatments in Inflammation and Allergy

• 

  Stellabody®

• 

  Stellabody® Technology in Infectious Disease – COVID-19 and beyond

• 

  Stellabody® Technology in Cancer Therapy

Publications (1)

2022 (1)

• Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
  Wines BD, Kurtovic L, Trist HM, Esparon S, Lopez E, Chappin K, Chan LJ, Mordant FL, Lee WS, Gherardin NA, Patel SK, Hartley GE, Pymm P, Cooney JP, Beeson JG, Godfrey DI, Burrell LM, van Zelm MC, Wheatley AK, Chung AW, Tham WH, Subbarao K, Kent SJ, Hogarth PM
  Front Immunol. 2022 Jul; 13:889372